• https://kelpondokbetung.tangerangselatankota.go.id/public/js/file/
  • This site is part of the Siconnects Division of Sciinov Group

    This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

    ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

    Registration

    CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology

    19 Feb, 2021

    Feb. 19, 2021-- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, Chief Executive Officer of Longeveron, has been invited to give a presentation titled “A Regenerative Medicine Approach to Aging Frailty” at the Intercontinental Summit on Aging & Gerontology being held virtually on March 8, 2021. He will discuss Longeveron’s ongoing clinical research program in Aging Frailty and Alzheimer’s disease, in addition to the regenerative medicine investigational clinical research field in general for diseases and conditions associated with aging.

    The Intercontinental Summit on Aging & Gerontology is hosted by the Sciinov Group and helps participants from universities and institutions to network with world-class scientists. This all-day online event unites researchers, scientists, and academicians to discuss and share knowledge in the emerging field of Aging & Gerontology.

    Information about the event can be found by visiting: agingcongress.com. A copy of the Company’s presentation will also be available on the Company’s website at: www.longeveron.com.

    About Longeveron Inc.
    Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

    Source: https://www.globenewswire.com/fr/news-release/2021/02/19/2178899/0/en/CEO-of-Longeveron-Inc-to-Present-at-the-Intercontinental-Summit-on-Aging-Gerontology.html


    Subscribe to our News & Updates